JP2024516575A5 - - Google Patents

Info

Publication number
JP2024516575A5
JP2024516575A5 JP2023562827A JP2023562827A JP2024516575A5 JP 2024516575 A5 JP2024516575 A5 JP 2024516575A5 JP 2023562827 A JP2023562827 A JP 2023562827A JP 2023562827 A JP2023562827 A JP 2023562827A JP 2024516575 A5 JP2024516575 A5 JP 2024516575A5
Authority
JP
Japan
Prior art keywords
nucleotide sequence
tlr7
immunomodulatory composition
motif
modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562827A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516575A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/025128 external-priority patent/WO2022221736A2/en
Publication of JP2024516575A publication Critical patent/JP2024516575A/ja
Publication of JP2024516575A5 publication Critical patent/JP2024516575A5/ja
Pending legal-status Critical Current

Links

JP2023562827A 2021-04-16 2022-04-15 最適化されたtlr7リガンド及びその使用 Pending JP2024516575A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163176128P 2021-04-16 2021-04-16
US63/176,128 2021-04-16
PCT/US2022/025128 WO2022221736A2 (en) 2021-04-16 2022-04-15 Optimized tlr7 ligands and uses thereof

Publications (2)

Publication Number Publication Date
JP2024516575A JP2024516575A (ja) 2024-04-16
JP2024516575A5 true JP2024516575A5 (cg-RX-API-DMAC7.html) 2025-04-18

Family

ID=81940670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562827A Pending JP2024516575A (ja) 2021-04-16 2022-04-15 最適化されたtlr7リガンド及びその使用

Country Status (5)

Country Link
US (1) US20240042019A1 (cg-RX-API-DMAC7.html)
EP (1) EP4323525A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024516575A (cg-RX-API-DMAC7.html)
CN (1) CN117203340A (cg-RX-API-DMAC7.html)
WO (1) WO2022221736A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4601656A1 (en) * 2022-10-12 2025-08-20 Pharmorage Pty Limited Modified oligonucleotides

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058166A2 (en) 2002-12-23 2004-07-15 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
JP2007526253A (ja) * 2004-02-19 2007-09-13 コーリー ファーマシューティカル グループ,インコーポレイテッド 免疫刺激性ウイルスrnaオリゴヌクレオチド
JP5331340B2 (ja) 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
WO2006063252A2 (en) * 2004-12-09 2006-06-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering rnas
EP1924284A1 (en) * 2005-09-14 2008-05-28 Hartmann, Gunther Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides
KR101343489B1 (ko) * 2007-07-09 2013-12-20 이데라 파마슈티칼즈, 인코포레이티드 안정화된 면역 조절성 rna(simra)화합물
WO2009132206A1 (en) 2008-04-25 2009-10-29 Liquidia Technologies, Inc. Compositions and methods for intracellular delivery and release of cargo
EP2396409A2 (en) * 2009-02-10 2011-12-21 Idera Pharmaceuticals, Inc. Synthetic rna-based agonists of tlr7
EP3263707A1 (en) 2009-03-17 2018-01-03 Rheinische Friedrich-Wilhelms-Universität Bonn Tlr8 ligand and uses thereof
US9187746B2 (en) * 2009-09-22 2015-11-17 Alnylam Pharmaceuticals, Inc. Dual targeting siRNA agents
CN110003066B (zh) 2013-11-18 2021-09-03 阿克丘勒斯治疗公司 用于rna递送的可电离的阳离子脂质
CN116549671A (zh) 2016-11-10 2023-08-08 川斯勒佰尔公司 用于递送mrna的改进的基于ice的脂质纳米颗粒制剂
WO2020214946A1 (en) 2019-04-18 2020-10-22 Translate Bio, Inc. Cystine cationic lipids
WO2020219941A1 (en) 2019-04-26 2020-10-29 Genevant Sciences Gmbh Lipid nanoparticles

Similar Documents

Publication Publication Date Title
US7115579B2 (en) Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
KR102434357B1 (ko) B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법
JP2025106391A (ja) 免疫賦活特性が減少したrna組み合わせおよび組成物
US7176296B2 (en) Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
JP2021526804A5 (cg-RX-API-DMAC7.html)
KR101835401B1 (ko) 키랄 핵산 어쥬번트
CN101460178B (zh) 用于tlr7和tlr8的稳定化的免疫调节性rna(simra)化合物
JP2023179428A (ja) メッセンジャーリボ核酸(mRNA)をコードする安定化された核酸
US7709449B2 (en) Nucleic acid-based compounds and methods of use thereof
US7105495B2 (en) Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
JP2019527694A (ja) B型肝炎ウイルス感染のためのRNAi薬
JPH08502040A (ja) ハイブリッド オリゴヌクレオチド ホスホロチオエート
WO1997029757A1 (en) Rnase l activators and antisense oligonucleotides effective to treat rsv infections
CN114206463A (zh) 脂质化合物和脂质纳米颗粒组合物
JP2008523094A5 (cg-RX-API-DMAC7.html)
CN115176009A (zh) 用于靶向pd-l1的方法和组合物
AU2010213795A1 (en) Synthetic RNA-based agonists of TLR7
JP2014532400A (ja) 免疫賦活用の二本鎖rna
EP2943251B1 (en) Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
US20240327847A1 (en) Compositions and methods for rna affinity
JP2024539093A (ja) 2’-デオキシ-2’-f-2’-c-メチルヌクレオチドを有するオリゴヌクレオチド
TW202313068A (zh) 用於抑制黏蛋白5AC(MUC5AC)表現之RNAi藥劑、其組合物及使用方法
JP2024541701A5 (cg-RX-API-DMAC7.html)
WO2003062258A1 (en) Rnase l activator-antisense complexes
KR100257972B1 (ko) 높은 키랄 순도의 포스포로티오에이트 결합기를 가지는 올리고뉴클레오티드